Trends & Technology  |   July 2020
Trends & Technology
Article Information
Airway Management / Central and Peripheral Nervous Systems / Infectious Disease / Pain Medicine / Patient Safety / Pharmacology / Respiratory System / Technology / Equipment / Monitoring / Trends & Technology
Trends & Technology   |   July 2020
Trends & Technology
ASA Monitor 7 2020, Vol.84, 36-37.
ASA Monitor 7 2020, Vol.84, 36-37.
Hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received placebo, according to preliminary analysis from a randomized, controlled trial of 1,063 patients that began in February. The Adaptive COVID-19 Treatment Trial (ACTT), sponsored by the National Institutes of Health National Institute of Allergy and Infectious Diseases (NIAID), is the first clinical trial launched in the United States to evaluate an experimental treatment for COVID-19.
On April 27, an independent data and safety monitoring board overseeing the trial shared interim analysis with the study team, noting that remdesivir was better than placebo for time to recovery, a metric often used in influenza trials. Recovery in this study was defined as being well enough for hospital discharge or returning to normal activity level.
0 Comments
Submit a Comment
Submit A Comment

Contributors must reveal any conflict of interest. Comments are moderated.

Name
Affiliation & Institution
I have a potential conflict of interest
Comment Title
Comment


This feature is available to Subscribers Only
ASA Member Login or Create an Account ×